Literature DB >> 20471408

In vivo nicotine exposure in the zebra finch: a promising innovative animal model to use in neurodegenerative disorders related research.

S L T Cappendijk1, D F Pirvan, G L Miller, M I Rodriguez, P Chalise, M S Halquist, J R James.   

Abstract

Nicotine improves cognitive enhancement and there are indications that neurodegenerative (age-related) cognitive disorders could be treated with nicotine-based drugs. The zebra finch is a well-recognized model to study cognitive functioning; hence this model could be used to study the effects of nicotine in neurodegenerative cognitive disorders. However, nicotine's in vivo physiological and behavioral effects have never been studied in the zebra finch. Here we present the first in vivo nicotine study in zebra finches. We evaluated the dose-response effects of nicotine on locomotor activity, song production, food intake and body weight. A liquid chromatography tandem mass spectrometry method was developed and validated for quantification of nicotine and cotinine in feces. The subcutaneous nicotine drug regiment (0.054-0.54mg/kg) induced physiologically significant values of nicotine and cotinine. The mid (0.18mg/kg) and high (0.54mg/kg) dose of nicotine promoted the development and expression of a sensitized response of song production and locomotor activity. Food intake and body weight were not affected following nicotine exposure. In conclusion, the zebra finch can be used as an innovative animal model not only in nicotine-related research studying cognitive functioning, but also in studies examining nicotine dependence and addictive mechanisms. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20471408     DOI: 10.1016/j.pbb.2010.04.025

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  8 in total

1.  Prenatal nicotine exposure enhances the trigeminocardiac reflex via serotonin receptor facilitation in brainstem pathways.

Authors:  C Gorini; H Jameson; A L Woerman; D C Perry; D Mendelowitz
Journal:  J Appl Physiol (1985)       Date:  2013-06-13

2.  Piloting a clinical laboratory method to evaluate the influence of potential modified risk tobacco products on smokers' quit-related motivation, choice, and behavior.

Authors:  Jenny E Ozga-Hess; Nicholas J Felicione; Stuart G Ferguson; Geri Dino; Daniel Elswick; Catherine Whitworth; Nicholas Turiano; Melissa D Blank
Journal:  Addict Behav       Date:  2019-08-21       Impact factor: 3.913

3.  Nicotine and carbon monoxide exposure from inhalation of cigarillo smoke.

Authors:  Bartosz Koszowski; Zachary R Rosenberry; Alieu Kanu; Lauren C Viray; Jennifer L Potts; Wallace B Pickworth
Journal:  Pharmacol Biochem Behav       Date:  2015-10-13       Impact factor: 3.533

4.  An examination of social and environmental determinants of secondhand smoke exposure among non-smoking adolescents.

Authors:  Elizabeth K Do; Kennedy C Bradley; Kendall Fugate-Laus; Kiranpreet Kaur; Matthew S Halquist; Laure Ray; Michell A Pope; Rashelle B Hayes; David C Wheeler; Bernard F Fuemmeler
Journal:  Tob Prev Cessat       Date:  2021-03-12

5.  Effect of an electronic nicotine delivery system with 0, 8, or 36 mg/mL liquid nicotine versus a cigarette substitute on tobacco-related toxicant exposure: a four-arm, parallel-group, randomised, controlled trial.

Authors:  Caroline O Cobb; Jonathan Foulds; Miao-Shan Yen; Susan Veldheer; Alexa A Lopez; Jessica M Yingst; Christopher Bullen; Le Kang; Thomas Eissenberg
Journal:  Lancet Respir Med       Date:  2021-04-12       Impact factor: 102.642

6.  Cigarette smokers' concurrent use of smokeless tobacco: dual use patterns and nicotine exposure.

Authors:  Nicholas J Felicione; Jenny E Ozga-Hess; Stuart G Ferguson; Geri Dino; Summer Kuhn; Ilana Haliwa; Melissa D Blank
Journal:  Tob Control       Date:  2020-02-12       Impact factor: 7.552

7.  Impact of smoked cannabis on tobacco cigarette smoking intensity and subjective effects: A placebo-controlled, double-blind, within-subjects human laboratory study.

Authors:  Erica N Peters; Evan S Herrmann; Carson Smith; Jess Alan Wilhelm; Bartosz Koszowski; Matthew Halquist; Leon Kosmider; Justin Poklis; Sage Roth; Stephan Bart; Wallace B Pickworth
Journal:  Exp Clin Psychopharmacol       Date:  2020-05-28       Impact factor: 3.492

8.  Triangulating abuse liability assessment for flavoured cigar products using physiological, behavioural economic and subjective assessments: a within-subjects clinical laboratory protocol.

Authors:  Catherine S Wall; Rose S Bono; Rebecca C Lester; Cosima Hoetger; Thokozeni Lipato; Mignonne C Guy; Thomas E Eissenberg; Warren K Bickel; Andrew J Barnes; Caroline O Cobb
Journal:  BMJ Open       Date:  2018-10-10       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.